Skip to main content

Advertisement

Table 4 Antidiabetic and concomitant pharmacotherapy with or without observed initiation of BOT

From: Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry

Treatment Total Population BOT(observed) BOT(not observed) p-value
(N = 31,008) (N = 6,705) (N = 24,303)
n (%) n (%) n (%)
Monotherapy     
 Metformin 19,866 (64.1) 4,235 (63.2) 15,651 (64.4) 0.06
 Sulfonylurea 4,532 (14.6) 1,012 (15.1) 3,520 (14.5) 0.21
 Glucosidase inhibitors 241 (0.8) 56 (0.8) 185 (0.8) 0.53
 Glitazones 158 (0.5) 33 (0.5) 125 (0.5) 0.92
 Glinides 1397 (4.5) 361 (5.4) 1,036 (4.3) <0.001
 DPP-4 inhibitor 4,141 (13.4) 1,023 (15.3) 3,118 (12.8) <0.0001
No. of OADs     <0.0001
 1 OAD 26,861 (86.6) 5,564 (83.0) 21,297 (87.6)  
 2 OADs 3,818 (12.3) 1,049 (15.6) 2,769 (11.4)  
  ≥ 3 OADs 329 (1.1) 92 (1.4) 237 (1.0)  
Concomitant medication     <0.0001
 no drug 16,959 (54.7) 3,409 (50.8) 13,550 (55.8)  
 1 drug 5,762 (18.6) 1,150 (17.2) 4,612 (19.0)  
 2 drugs 2,697 (8.7) 566 (8.4) 2,131 (8.8)  
  ≥ 3 drugs 5,590 (18.0) 1,580 (23.6) 4,010 (16.5)  
  1. Legend: BOT basal supported oral therapy, DPP dipeptidyl peptidase, OAD oral antidiabetic drug. Test for independence between groups by means of Fisher’s exact test